DDInter1592 DDInter1576
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Rifapentine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Regorafenib
Rifapentine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Rifapentine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Rifapentine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Rifapentine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound)